Clinical trial · Observational
The SENTRY Study: Testing Whether Changes in Platelet RNA Enhance the Early Diagnosis of Ovarian Cancer
NCT06665945CI-TRIAL-00107688SENTRYrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the SENTRY (Stability Enhanced Transcriptional Analytics) Study is to test whether combining a unique analytical approach with changes in platelet RNA expression accurately diagnoses ovarian cancer. Using retrospective data, the investigators have developed an approach that appears to accurately classify ovarian cancer with relatively high sensitivity and specificity. The SENTRY Study will build upon these retrospective analyses to prospectively recruit women with ovarian cancer or an ovarian mass (and healthy control women), obtain platelet RNA samples from whole blood, and perform validation analyses to test our hypothesis.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Platelet RNA expression | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Women with a Recent Diagnosis of an Ovarian or Pelvic Mass (n=215)
- interventionNames
- Diagnostic Test: Platelet RNA expression
- label
- Control Women without Ovarian Cancer (n=30)
- interventionNames
- Diagnostic Test: Platelet RNA expression
Primary outcomes (1)
- measure
- Early-Stage Ovarian Cancer Detection
- timeFrame
- Following informed consent (study visit 1, day 1).
- description
- The goal is to determine if changes in platelet RNA expression accurately diagnoses ovarian cancer. This outcome will report the number of true positive, true negative, false positive, and false negative results from this assay.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 21 Years
Show eligibility criteria text
Study Populations 1 and 2: Women with a Recent Diagnosis of an Ovarian or Pelvic Mass (n=215) Inclusion Criteria: 1. Women aged 21 years or older 2. Diagnosed with any type of ovarian or pelvic mass 3. Treatment naïve for current ovarian cancer (if cancer has been diagnosed) 4. The treating medical provider(s) are planning to perform a biopsy, surgery, or other diagnostic procedure to further evaluate the ovarian or pelvic mass (if not already diagnosed prior to consent) Exclusion Criteria: 1. Any other active malignancy 2. Other diagnosis of any cancer within the last 6 months except for non-melanoma skin cancer or carcinoma in situ of the cervix 3. Treatment for any cancer within the last 6 months except for non-melanoma skin cancer or carcinoma in situ of the cervix. Adjuvant endocrine therapy or other maintenance therapy is allowed. 4. Currently receiving chemotherapy, radiation therapy, or other treatments for ovarian cancer 5. Has already undergone complete ovarian mass resection 6. Unable to provide blood sample Study Population 3: Control Women without Ovarian Cancer (n=30) Inclusion Criteria: 1\. Women aged 21 years or older Exclusion Criteria: 1. Any active malignancy or diagnosis of cancer within the last 6 months except for non-melanoma skin cancer or carcinoma in situ of the cervix 2. Treatment for any cancer within the last 6 months except for non-melanoma skin cancer or carcinoma in situ of the cervix 3. Hospitalization or surgery (other than minor surgery such as mole removal) within the last 8 weeks 4. Renal failure (defined as eGFR \< 60 mL/min/1.73m² or on dialysis) 5. Liver failure (defined as having hepatic encephalopathy of any degree, OR moderately severe coagulopathy defined as INR ≥ 1.5, OR known cirrhosis, OR ALT of ≥ 10X ULN, OR total bilirubin of ≥ 3.0 mg/dL, OR diagnosis of liver failure) 6. Decompensated or end-stage heart failure (defined as ACC/AHA Stage C or Stage D heart failure) 7. Poorly controlled diabetes mellitus (defined as a HbA1c \> 9.0%) 8. Venous thrombosis, myocardial infarction, or stroke within the last 8 weeks 9. Currently pregnant or have been pregnant within the last 12 weeks 10. Any blood product transfusion within the last 8 weeks 11. Personal history of ovarian cancer at any time 12. History of bilateral salpingo-oophorectomy 13. History of oophorectomy 14. Unable to provide blood sample
References
Publications (0)
Data not yet available
No reference posted for this study.